Small molecule · developed by TAKEDA PHARMACEUTICAL CO
Soticlestat is an investigational small-molecule drug studied in Healthy Volunteers, Developmental and/or Epileptic Encephalopathies, Lennox Gastaut Syndrome (LGS).
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04938427 | Phase 3 | Lennox Gastaut Syndrome (LGS) | Completed | TAK |
| NCT03166215 | Phase 1/2 | Developmental and/or Epileptic Encephalopathies | Completed | TAK |
| NCT05602818 | Phase 1 | Healthy Volunteers | Completed | TAK |
| NCT04992442 | Phase 1 | Healthy Volunteers | Completed | TAK |
| NCT02906813 | Phase 1 | Healthy Volunteers | Completed | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Developmental and/or Epileptic EncephalopathiesHealthy VolunteersLennox Gastaut Syndrome (LGS)
Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →